Francis Mhimbira

In the News

Bagamoyo academy pupils briefed on product testing at IHI

(Bagamoyo) The IHI Vector Control Product Testing Unit in Bagamoyo today hosted pupils from Stephen Tito Academy who visited the IHI Kingani site to learn about malaria research. IHI’s Emmanuel …

IHI chief: Hub for innovative minds in the pipeline

(Dar es Salaam) Ifakara Health Institute (IHI) Chief Executive Director Dr. Honorati Masanja has unveiled plans to establish an innovation hub in the Institute’s birthplace – Ifakara. IHI Chief Executive …

Recent Projects

Sustainable, Healthy, Learning Cities and Neighbourhoods

The Sustainable, Healthy, Learning Cities and Neighbourhoods is an exciting project in which IHI works with a consortium of partners from Asia and Africa to 1) develop capacity for improved …

Development of a new tool for malaria mosquito surveillance to improve vector control

Malaria transmission is influenced not only by vector abundance, but as well by demographic traits such as vector species and age structure, as these influence the intensity by which the …

Francis Mhimbira

Research Scientist and Head of Interventions & Clinical Trials

Dr. Francis Mhimbira is an epidemiologist and a research scientist based at Ifakara Health Institute. Dr. Mhimbira received his medical degree at Muhimbili University College of Health Sciences (MUCHS), Tanzania, and did a Masters degree in Epidemiology from The University of Melbourne, Australia. He works within the intervention thematic group and conducts research on TB clinical trials for new drugs and vaccines. His work also involves evaluating new TB diagnostic tools and epidemiological studies on TB and co-infections (such as HIV, helminth and respiratory pathogens). Francis also does operational research to improve TB case detection and improve TB treatment outcomes. He is currently a national and principal investigator of Phase III clinical trial (NC-006) of new TB drugs and regimen. Francis is currently the Head of Interventions and Clinical Trials Department.

View Dr. Mhimbira’s Research Interests and Publications

Projects

Evaluation of combinations of bedaquiline, moxifloxacin, PA‐824 and pyrazinamide for treatment of newly-diagnosed TB patients

Evaluation of efficacy, safety and tolerability of a three-drug regimen (Moxifloxacin+PA‐824+Pyrazinamide) for TB and MDR-TB

A PIXELBASE DESIGN
© Ifakara Health Institute (IHI), 2016